Get the Stockscreener App
8.90
1.77%
-0.16
After Hours:
8.96
0.06
+0.67%
Capricor Therapeutics Inc stock is traded at $8.90, with a volume of 2.39M.
It is down -1.77% in the last 24 hours and up +41.49% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$9.06
Open:
$9.14
24h Volume:
2.39M
Relative Volume:
0.41
Market Cap:
$517.44M
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-3.8478
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
+1.02%
1M Performance:
+41.49%
6M Performance:
-69.42%
1Y Performance:
+33.83%
1-Day Range:
$8.84
$9.275
1-Week Range:
$8.375
$9.79
52-Week Range:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
8.90 | 486.62M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - MarketBeat
CAPRICOR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Capricor’s FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope - Stocktwits
CAPRCapricor Therapeutics Inc Revenue Breakdown - Finviz
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Inv - The National Law Review
Capricor Therapeutics Stock Short Interest Rises to 42.13% - Moomoo
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Morningstar
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Capricor Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
Kaplan Fox Class Action Reminder: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Lead Plaintiff Deadline is September 28, 2026 - NewMediaWire
Robbins LLP Reminds Capricor Therapeutics, Inc. - GlobeNewswire
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - TMX Newsfile
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline - marketscreener.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GuruFocus
CAPRICOR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 - NewMediaWire
CAPRICOR THERAPEUTICS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCAPR - PR Newswire
Faruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of ... - pmg-ky3.com
Capricor Therapeutics Shareholder Alert: ClaimsFiler - GlobeNewswire
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026 - FinancialContent
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline - PR Newswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - natlawreview.com
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Capricor - globenewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. LawsuitCAPR - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
CAPR Legal Notice: BFA Law Notifies Capricor Therapeutics Investors that Lost Money of the Imminent September 28 Securities Fraud Class Action Deadline - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Notice of September 28, 2026 - GlobeNewswire
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire
Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Securities Class Action DeadlineContact the Firm Before September 28, 2026 - NewMediaWire
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 28, 2026 DeadlineRGRD Law - marketscreener.com
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT - GlobeNewswire
CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure - PR Newswire
CAPR DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Datavault AI Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CAPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ca - The National Law Review
Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline - PR Newswire
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - TradingView
CAPR FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionCAPR - ACCESS Newswire
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.05%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):